Introduction
============

To the best of our knowledge circulating miRNAs in TRAPS, as well as in other monogenic autoinflammatory disorders have never been investigated.

Objectives
==========

To evaluate circulating microRNAs (miRNAs) levels in patients with tumor necrosis factor-receptor associated periodic syndrome (TRAPS), in comparison to healthy controls, and to correlate their levels to parameters of disease activity and/or disease severity.

Methods
=======

Expression levels of circulating miRNAs were measured by Agilent microarrays in 29 serum samples from 15 TRAPS patients carrying mutations known to be associated with high disease penetrance and 8 healthy controls. Differentially expressed and clinically relevant miRNAs were detected using GeneSpring GX software.

Results
=======

We identified a 6 miRNAs signature able to discriminate TRAPS from healthy controls. Moreover, 4 miRNAs were differentially expressed between patients treated with the interleukin (IL)-1 receptor antagonist anakinra and untreated patients. Of these, miR-92a-3p expression was found to be reduced in untreated patients, while its expression levels were similar to healthy controls in samples obtained during anakinra treatment. MiR-92b levels were inversely correlated with the number of fever attacks/year during the 1^st^ year from the index attack of TRAPS, while miR-377-5p levels were positively correlated with serum amyloid A (SAA) circulating levels.

Conclusion
==========

Serum miRNAs levels show a baseline pattern in TRAPS, and may serve as potential markers of response to therapeutic intervention.
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